key: cord-0808681-cpdcy6dy authors: Choi, Yu Jeong; Roh, Juhye; Kim, Sinyoung; Lee, Kyung‐A; Park, Younhee title: Comparison of IL‐6 measurement methods with a special emphasis on COVID‐19 patients according to equipment and sample type date: 2021-12-14 journal: J Clin Lab Anal DOI: 10.1002/jcla.24182 sha: f321c8076dd32223cabee6e938929e61badb574c doc_id: 808681 cord_uid: cpdcy6dy BACKGROUND: Interleukin‐6 (IL‐6) is a multifunctional cytokine associated with various diseases, including coronavirus disease (COVID‐19). Although IL‐6 levels can be assessed using serum samples, use of the AFIAS (Boditech Med Inc.) automated immunoassay analyzer enables quick and simple measurement of IL‐6 levels in both serum and whole blood specimens. This study aimed to assess the correlation between IL‐6 measurements obtained from the AFIAS IL‐6 assay and Elecsys IL‐6 assay (Roche Diagnostics). Additionally, utilization of the AFIAS IL‐6 assay was evaluated. METHODS: The IL‐6 levels from 113 serum samples quantified using two assay systems were evaluated for their degree of correlation. Meanwhile, the linearity, analytical sensitivity, and precision/reproducibility of the AFIAS IL‐6 assay were also assessed. RESULTS: Quantification of IL‐6 with the AFIAS IL‐6 and Elecsys IL‐6 assays showed excellent agreement (kappa 0.802) and were found to be correlated (y = −0.2781 + 1.068x; 95% confidence interval: 1.007–1.124). AFIAS IL‐6 showed good analytical performances. IL‐6 levels were significantly higher in deceased patients compared to those with non‐complicated disease and those who were intubated (p = 0.002 and p < 0.0001, respectively). Finally, IL‐6 levels more accurately predicted poor prognosis in patients, than did C‐reactive protein (area under the curve, 0.716 vs. 0.634). CONCLUSION: The overall analytical performance of the AFIAS assay was comparable to that of the Elecsys IL‐6 assay. In light of the ongoing COVID‐19 pandemic, the AFIAS may be an attractive tool for measuring IL‐6 levels. and PI3K-PKB/Akt pathways. 2 Abnormal activation of these pathways leads to various pathologic conditions including cancer, multiple sclerosis, rheumatoid arthritis, diabetes, anemia, inflammatory bowel disease, Crohn's disease, and Alzheimer's disease. 3 IL-6 is an established therapeutic target in some of these pathologies, thereby playing an important role in their management. [4] [5] [6] [7] [8] In addition, IL-6 production is elevated in acute inflammatory reactions, which are associated with trauma and infection. 1 IL-6 levels can therefore be used to predict future complications or detect missed injuries in trauma patients. 9, 10 Additionally, sequential measurement of in patients admitted to the intensive care unit (ICU) can be useful for evaluating the severity of systemic inflammatory response syndrome (SIRS), sepsis, and septic shock. 11, 12 Recent studies have revealed that IL-6 is also related to the prognosis of coronavirus disease . 13 Coronaviruses can cause acute respiratory distress syndrome (ARDS) via excessive activation and dysregulation of host immune responses, such as the cytokine release syndrome. 14, 15 Reports comparing IL-6 levels between patients with complicated disease (ARDS, ICU admission) and non-complicated disease revealed that the IL-6 level was significantly elevated in the former group compared to that in the latter group. [16] [17] [18] [19] [20] [21] In fact, one study showed that baseline IL-6 levels were positively correlated with bilateral pulmonary involvement and maximum body temperature. 18 Furthermore, IL-6 levels in patients after receiving treatment were significantly reduced as their pulmonary computed tomography images showed improvement, whereas patients experiencing clinical deterioration had increased IL-6 levels. Another study analyzing the risk factors for ARDS and death in patients with COVID-19 observed elevated IL-6 levels associated with both ARDS and death. 21 These circumstances necessitate a method for measuring IL-6 levels in a simple and timely manner. The AFIAS IL-6 assay (Boditech Med Inc.) is a fluorescence immunoassay (FIA) for the quantitative detection of IL-6 in not only serum and plasma samples but also in whole blood samples. The assay does not require strict maintenance and comprises a simple two-step process, eliminating the need for highly trained personnel to run the protocol. Moreover, the size of the instrument is smaller than that used in conventional methods of measurement, such as the Elecsys IL-6 assay (Roche Diagnostics), enabling potential use at outpatient clinics and in smallsized laboratories. The more conventional Elecsys IL-6 assay is an electro-chemiluminescence immunoassay (ECLIA) that can analyze serum and plasma samples, however, cannot process whole blood samples; moreover, the machine is quite large and requires strict maintenance. This study aimed to compare the analytical performance of the AFIAS IL-6 assay with that of the Elecsys IL-6 assay system by evaluating its correlation. We hypothesize that the IL-6 measurement obtained using the AFIAS IL-6 assay will correlate well with that obtained with Elecsys IL-6 assay, making the AFIAS IL-6 assay a suitable alternative. We also hypothesize that IL-6 levels measured in serum and whole blood will correlate sufficiently such that the two types of samples may be used interchangeably. A total of 113 serum samples from 34 patients, collected during January 2021, were analyzed. An additional 40 whole blood samples were simultaneously collected from these patients. Patient demographics are shown in Table 1 . The mean age of the patients was 60 years (range: 11-84 years). The male to female ratio was 1.27:1. Twenty-three (67.6%) patients were diagnosed with COVID-19, from whom 99 samples were collected. Serum samples were collected in SST tubes (AB Medical; REF 321502) and centrifuged at 3,500 rpm for 10 min before analysis. Whole blood samples were collected in ethylenediaminetetraacetic acid (EDTA) tubes (AB Medical; REF 410303) and analyzed without further processing. Blood samples were drawn regardless of specific time or fasting state. IL-6 levels were quantified on the same day that the samples were collected using both the Elecsys IL-6 (Cobas e602 analyzer) and AFIAS IL-6 assays according to the manufacturers' recommendations. The Elecsys IL-6 assay utilized the ECLIA method, whereas the AFIAS IL-6 assay used the FIA method. Unlike Elecsys IL-6, AFIAS IL-6 included EDTA whole blood as a recommended specimen. Moreover, the Elecsys assay used a fully automated online analyzer, while AFIAS assay used a partially automated offline analyzer. The duration of the assays was 18 and 12 min for Elecsys IL-6 and AFIAS IL-6, respectively. Their analytical performance data, as presented by the manufacturers, are summarized in Table 2 . Results not quantified by either assay were excluded from the correlation analysis. 22 This research was conducted in accordance with all relevant national regulations, institutional policies, and the tenets of the Positive controls at different concentrations (9.0 pg/ml, 42.61 pg/ml, and 1,274.0 pg/ml) were provided by the manufacturer and tested in duplicates twice per day for 21 days. Using this data, the inter-and intra-assay precision were evaluated. The acceptance criterion was set to a coefficient of variation (CV%) <10%. 23 To verify the linearity of the AFIAS IL-6 assay, two serum samples with low (2 pg/ml) and high concentrations (2,039 pg/ml) were mixed in the following proportions to produce five concentrations: 4:0, 3:1, 2:2, 1:3, and 0:4. The high and low concentrations were verified using Elecsys IL-6 assay. The five concentrations were measured in duplicate. 24 The allowable error criteria were set at ≤10% residual, except for the lowest level. To assess the analytical sensitivity of the AFIAS IL-6 assay, calibrators with appropriate concentrations of 2 pg/ml and 9 pg/ml, as well as the assay buffer were used. The assay buffer was tested 8 times per day for 3 days using three different lots. Rank position formula was used for the limit of blank (LOB) calculation (Rank position = (72 × 0.95) +0.5), and the LOB was selected as the highest values obtained from all lots. The results were then sorted in ascending order, and the 68 th and 69 th results were selected according to formula (LOB = Rank 68 value +0.5 X (Rank 69 value -Rank 68 value). Next, the limit of detection (LOD) was determined by creating four mixtures with the following calibration solution (2 pg/ml): diluent (Gibco. No. 26050-088) proportions: 1:3, 1:1, 1:0.33, and 1:0. Each solution was run five times on 3 days using three different lots. Additionally, the limit of quantitation (LOQ) was determined by mixing 1.5, 1.8, 2, 2.3, and 2.5 pg/ml materials with 9 pg/ml calibrator and diluent (Gibco). These analyses were performed four times on three different days with three different lots. LOQ was set as the lowest concentration with <20% of total allowable error (TE). To determine whether any significant differences in IL-6 values occurred based on the condition of the patient, samples were divided into the following three groups: samples obtained from those with non-complicated disease, those requiring ventilation, and deceased patients. IL-6 and C-reactive protein (CRP) levels of samples collected on the same day were compared. CRP levels were tested using the Cobas8000 system (Roche). Samples with IL-6 levels below the lower limit of detection (LLOD; 2.0 pg/ml) were excluded. Bland-Altman analysis, and Cohen's kappa coefficients were used to evaluate the correlation and agreement between the two assays. Table 2 ). The within-run, within-laboratory, between-lot, between-person, and between-site imprecision values are summarized in Table 3 . All % CVs were within 10%, indicating good assay precision. Table S1 . The comparison between the Elecsys IL-6 and AFIAS IL-6 assays is shown in Figure 2 . Figure 2B ). The comparison between serum and whole blood IL-6 levels measured using the AFIAS assay is shown in Figure S1 . Of the 40 samples collected, 34 were quantified and analyzed as both serum and whole blood. The regression line was y = 0.05064 + 0.9647x (95% CI of the slope: 0.877-1.077, 95% CI of the y-intercept: −0.1489-0.2197), and the correlation coefficient was 0.978. The average bias between the two types of samples was 0.024 Log pg/ml (5.14%) (whole blood -serum), with no specific trend for increasing IL-6 levels. The categorical distribution of all serum samples according to the cut-off value of each assay (7 pg/ml) is summarized in Table 4 . Overall, we found that the analytical performance of the AFIAS IL-6 assay was comparable to that of the Elecsys IL-6 assay. The assay showed linearity throughout a wide concentration range (2-2,039 pg/ml). The linear range of the assay was wider than that of a previously reported time-resolved lateral flow immunoassay (5-500 pg/ml). 21 The within-run, within-laboratory, between-lot, between-person, and between-site imprecision rates were all <10%, indicating that the assay had good precision. The results yielded by AFIAS IL-6 and Elecsys IL-6 assays showed good agreement (kappa of 0.802). However, significant systemic error was found in the correlation study between AFIAS IL-6 and Elecsys IL-6 assays as the 95% CI of the slope and y-intercept did not include 1.0 and 0.0, respectively. Moreover, the bias percentage was slightly higher (0.66%) than the total error allowable for p < 0.05 (33.6%) as defined by Aziz et al. 26 The results obtained by the AFIAS IL-6 assay for whole blood and serum samples exhibited for each assay was applied to examine the categorical distribution of the samples used in this study. The two assays exhibited good agreement, 25 and only eight samples showed discrepant results. While the specific values were all near the cut-off value of 7 pg/ ml, all eight discrepant samples showed results above the cut-off value on measurement using the Elecsys assay but not with the AFIAS assay. We found that deceased patients and those who required ventilation had significantly higher IL-6 levels than those with noncomplicated disease. An association between elevated IL-6 levels and progression to ARDS and death in COVID-19 patients has previously been observed. 27 Despite these limitations, our results demonstrated the overall analytical performance of the AFIAS IL-6 assay was comparable to that of the Elecsys IL-6 assay. Since the AFIAS analyzer does not require strict maintenance, can measure IL-6 levels in whole blood specimens, and involves only a two-step process, no highly trained personnel are required for its processing. Furthermore, the size of the equipment is smaller than those required in conventional methods; thus, it can be used conveniently in the outpatient setting and small laboratories. In addition, the instrument used for the AFIAS IL-6 assay can measure COVID-19 and flu antigens simultaneously. These traits make the AFIAS IL-6 assay an attractive measurement option, especially in light of the ongoing COVID-19 pandemic. The authors declare no competing interests. YP and SK contributed to the conception and design. JR and YP contributed to acquisition of data, analysis and interpretation of data, and critical revision of the study for important intellectual content. YJC contributed to drafting the article and statistical analysis., SK and KAL gave administrative support. SK, KAL, and YP are involved in supervision. All authors have accepted responsibility for the entire content of this study and approved its submission. All authors have access to the entirety of the data underlying this study. Access to the data can be granted at any time upon reasonable request. Younhee Park https://orcid.org/0000-0001-8458-1495 Interleukin-6 STAT3 signaling: anticancer strategies and challenges A panoramic review of IL-6: structure, pathophysiological roles and inhibitors Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence IL-6 family cytokines: key inflammatory mediators as biomarkers and potential therapeutic targets Targeting of interleukin-6 for the treatment of rheumatoid arthritis: a review and update Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice IL-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance Correlation between IL-6 levels and the systemic inflammatory response score: can an IL-6 cutoff predict a SIRS state? The early second hit in trauma management augments the proinflammatory immune response to multiple injuries Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for sepsis Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis Interleukin-6 in Covid-19: a systematic review and meta-analysis Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology Coronavirus infections and immune responses Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia Clinical features of patients infected with 2019 novel coronavirus in Wuhan The role of interleukin-6 in monitoring severe case of coronavirus disease 2019 Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) Rapid and sensitive detection of interleukin-6 in serum via time-resolved lateral flow immunoassay Measurement Procedure Comparison and Bias Estimation Using Patient Samples, 3 rd ed. CLSI guideline EP09. Clinical and Laboratory Standards Institute Evaluation of Precision of Quantitative Measurement Porcedures, 3 rd ed. CLSI guideline EP5. Clinical and Laboratory Standards Institute Evaluation of the linearity of quantitative measurement procedures, 2 nd ed. CLSI guideline EP06. Clinical and Laboratory Standards Institute Interrater reliability: the kappa statistic Biological variation of immunological blood biomarkers in healthy individuals and quality goals for biomarker tests Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Comparison of IL-6 measurement methods with a special emphasis on COVID-19 patients according to equipment and sample type